Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 4/20 | 0.44 |
| ▸ | PTGIR | P43119 | 10/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 7/20 | 0.44 |
| ▸ | ATP4A | P20648 | 1/20 | 0.38 |
| ▸ | ATP4B | P51164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7959954 | 0.91 | MEN1 (0.48) | PSMB8PSMB5ALDH1A1LMNAMEN1 | |
| SCHEMBL11301037 | 0.85 | PTGIR (0.47) | PSMB8PSMB5ALDH1A1PTGIRTBXA2R | |
| SCHEMBL5504988 | 0.84 | TAAR1 (0.53) | PSMB8PSMB5ALDH1A1LMNAMEN1 | |
| SCHEMBL5234354 | 0.84 | ALDH1A1 (0.46) | PSMB8PSMB5ALDH1A1LMNAMEN1 | |
| SCHEMBL4136821 | 0.84 | MEN1 (0.46) | PSMB8PSMB5ALDH1A1LMNAMEN1 | |
| Hydrochloric Acid SCHEMBL70924 | 0.83 | TAAR1 (0.51) | PSMB8PSMB5ALDH1A1LMNAMEN1 | |
| SCHEMBL7958900 | 0.82 | PTGIR (0.46) | PSMB8PSMB5ALDH1A1LMNAHPGD | |
| SCHEMBL806348 | 0.82 | ALDH1A1 (0.54) | PSMB8PSMB5ALDH1A1LMNAMEN1 | |
| SCHEMBL5235417 | 0.82 | MEN1 (0.48) | PSMB8PSMB5ALDH1A1LMNAMEN1 | |
| SCHEMBL5761000 | 0.82 | ALDH1A1 (0.48) | PSMB8PSMB5ALDH1A1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122213-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-04-17 | — | — | US | disclosed |
| US-12195478-B2 | Opioid receptor modulators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-01-14 | — | — | US | disclosed |
| EP-4487913-A2 | OPIOID RECEPTOR MODULATORS | The Trustees Of Columbia University In The City Of New York (US) | 2025-01-08 | — | — | EP | disclosed |
| EP-3224261-B1 | OPIOID RECEPTOR MODULATORS | UNIV COLUMBIA (US) | 2024-09-18 | — | — | EP | disclosed |
| US-11840541-B2 | Opioid receptor modulators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840541-B2 | Opioid receptor modulators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840541-B2 | Opioid receptor modulators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230271976-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230271976-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230271976-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-31 | — | — | US | disclosed |
| US-6800637-B2 | Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines | WYETH | 2004-10-05 | — | — | US | disclosed |
| US-20040138222-A1 | Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines | WYETH | 2004-07-15 | — | — | US | disclosed |
| WO-2004024734-A1 | ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | WYETH (US) | 2004-03-25 | — | — | WO | disclosed |
| US-6323235-B1 | CARDIOVASCULAR DISORDERS, ANTIISCHEMIC AGENTS AND ENZYME INHIBITORS | OHTAKE ATSUSHI (JP) | 2001-11-27 | — | — | US | disclosed |
| US-6043264-A | A THROMBOXANE A2 RECEPTOR ANTAGONIST FOR TREATING HYPERTENSION, THROMBOSIS, ISCHEMIC HEART DISEASES, CIRCULATORY DISEASES, ARTERIOSCLEROSIS, PLATELET FUNCTION DISORDER, HYPERLIPIDEMIA, NEPHRITIS OR ASTHMA | TORAY INDUSTRIES, INC. (JP) | 2000-03-28 | — | — | US | disclosed |
| EP-0751126-A1 | BENZENE-FUSED HETEROCYCLIC DERIVATIVE AND USE OF THE SAME | TORAY INDUSTRIES, INC. (JP) | 1997-01-02 | — | — | EP | disclosed |
| EP-0009780-B1 | OCTAHYDRO-1H-BENZO(4,5)FURO(3,2-E)ISOQUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-02-24 | — | — | EP | disclosed |
| US-4260761-A | Intermediates for the preparation of octahydro-1H-benzo[4,5]furo[3,2,-e]-isoquinoline analgesic and narcotic antagonistic compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-04-07 | — | — | US | disclosed |
| US-4243668-A | Octahydro-1H-benzo[4,5]furo[3,2-e]-isoquinoline analgesic and narcotic antagonistic compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-01-06 | — | — | US | disclosed |
| EP-0009780-A2 | Octahydro-1H-benzo(4,5)furo(3,2-e)isoquinoline derivatives, process for their preparation and pharmaceutical compositions containing them | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195478-B2 | Opioid receptor modulators | OPRM1, OPRL1, OPRD1 | PSMB8 2285/4885PSMB5 1136/4885ALDH1A1 2316/4885 |
| US-20040138222-A1 | Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines | HTR5A, TPH1, DBH | PSMB8 4670/4885PSMB5 2057/4885ALDH1A1 364/4885 |
| US-20250122213-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRD1 | PSMB8 2285/4885PSMB5 1136/4885ALDH1A1 2316/4885 |
| US-20230271976-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRD1 | PSMB8 2285/4885PSMB5 1136/4885ALDH1A1 2316/4885 |
| US-11840541-B2 | Opioid receptor modulators | OPRM1, OPRL1, OPRD1 | PSMB8 2267/4885PSMB5 1888/4885ALDH1A1 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.